Exkivity™ (mobocertinib) – New orphan drug approval

- On September 15, 2021, Takeda announced the FDA approval of Exkivity (mobocertinib), for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
    - This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
- NSCLC is the most common form of lung cancer, accounting for approximately 85% of new lung cancer cases. Patients with EGFR exon 20 insertion mutation NSCLC make up approximately 1 to 2% of patients with NSCLC.
- Exkivity is a tyrosine kinase inhibitor specifically designed to selectively target EGFR exon 20 insertion mutations.
- The efficacy of Exkivity was established in an open-label, multicohort study using a pooled subset of patients with EGFR exon 20 insertion mutation-positive metastatic or locally advanced NSCLC whose disease had progressed on or after platinum-based chemotherapy. Patients received Exkivity until disease progression or intolerable toxicity. The efficacy population consisted of 114 patients. The major efficacy outcome measure was overall response rate (ORR).
    - The ORR was 28% (95% CI: 20, 37).
    - The median duration of response was 17.5 months (95% CI: 7.4, 20.3).
- Exkivity carries a boxed warning for QTc prolongation and torsades de pointes.
- Additional warnings and precautions for Exkivity include interstitial lung disease/pneumonitis, cardiac toxicity, diarrhea, and embryo-fetal toxicity.
- The most common adverse reactions (> 20%) with Exkivity use were diarrhea, rash, nausea, stomatitis, vomiting, decreased appetite, paronychia, fatigue, dry skin, and musculoskeletal pain. The most common (≥ 2%) Grade 3 or 4 laboratory abnormalities were decreased lymphocytes, increased amylase, increased lipase, decreased potassium, decreased hemoglobin, increased creatinine, and decreased magnesium.
- The recommended dosage of Exkivity is 160 mg orally once daily until disease progression or unacceptable toxicity.
    - Patients with locally advanced or metastatic NSCLC should be selected for treatment with Exkivity based on the presence of EGFR exon 20 insertion mutations. Information on FDA-approved tests is available at: http://www.fda.gov/CompanionDiagnostics.

Continued . . .

- Takeda’s launch plans for Exkivity are pending. Exkivity will be available as a 40 mg capsule